Obinutuzumab Delays Disease Progression in CLLMonthly Prescribing Reference… obinutuzumab (GA101) plus chlorambucil helped patients with previously untreated chronic lymphocytic leukema live significantly longer without their disease worsening (progr…
|
Pneumonie à Pneumocystis : une complication des traitements par rituximab
Journal International de Médecine (Inscription) La pneumonie à Pneumocystis (PP) reste une infection fongique grave affectant les malades immunodéprimés. Les défenses immunitaires principales contre ce germe opportuniste sont constitués classiquement par les lymphocytes T CD4 +. Mais des études … |
Roche antibody tops Rituxan in blood cancer CLLPMLiVERoche said updated results from a phase III study of obinutuzumab (formerly GA101) showed the anti-CD20 antibody improved progression-free survival (PFS) in people with CLL compared to its establishe…
|
Genentech’s Obinutuzumab (GA101) Delayed Disease Progression Longer …
Wall Street Journal … monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan(R) (rituximab … |
|
Genentech’s Obinutuzumab (GA101) Delayed Disease Progression Longer …
Fort Mills Times … monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab … |
|
Biogen – Ahead of Q2 Earnings on Thursday
Proactive Investors USA & Canada AVONEX® (interferon beta-1a), TYSABRI® (natalizumab), and RITUXAN® (rituximab) are Biogen’s other primary drugs in the MS indication. These three brought in the vast majority of the company’s $1.4 B in quarterly revenues ($736 million, $275 million, … |
|
NICE ‘minded to say no’ to MabThera
PharmaTimes NICE has been examining MabThera (rituximab)’s use in its licensed indication for inducing remission, in combination with glucocorticoids, in adults with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, an inflammatory autoimmune … |
|
UK’s NICE calls for more data to consider Roche drug for a type of vasculitis
The Pharma Letter UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published draft guidance on Swiss drug major Roche’s (ROG: SOX) blockbuster cancer drug MabThera (rituximab), which is also licensed for inducing … NICE demands more data from Roche for MabThera in rare autoimmune diseasePMLiVE |
|
GAUGUIN: Higher Obinutuzumab Dose Shows Promise in Non-Hodgkin …
Cancer Network “Given that CD20 has proved to be a highly successful target antigen for immunotherapeutic approaches in hematologic malignancies, the development of novel anti-CD20 antibodies with functional activity different from that of rituximab may translate to … |
|
Promising Radioimmunotherapy Option for Some Lymphomas
Cancer Network A phase I/II study found that radioimmunotherapy with 177Lu and the anti-CD20 antibody rituximab along with the chelator DOTA is safe and feasible for treatment of relapsed follicular, mantle cell, or other indolent lymphomas. “Radioimmunotherapy … |